Siga has a promising vaccine that's in phase 1 trials. They are attempting to develope vaccines for various diseases and infections by spreading an antibody that inhibits growth. Siga's patented technology strips protein to readily clear bacteria. Siga drugs aim to boost childrens immune systems to the level of adults. The U.S. strep throat market is about $300 million and effects about 32 million children a year.
Seperately, Siga is in the early stages of developing vaccines for periodontal disease, and sexually transmitted diseases like genital ulcers, AIDS, genital warts, and cervial carcinoma. Siga has alliances for all these programs, but is looking for a significant partnership deal with a major pharmaceutical company for its vector delivery system, and a partner for its vaccines when they hit later clinical stages.
With the strep-throat market alone valued at $300 million, the company see large market opportunities. Pooling the potential vaccines and alliances the company has built, the company is worth more than the $13.9 million that the stock market currently values this firm,let alone its IPO value of $34 million.
Would be interested in your perspectives concerning Siga and its potential. |
